FCAR, Fc fragment of IgA receptor, 2204

N. diseases: 38; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.010 Biomarker disease BEFREE In vivo, CD89 transgenic mice are protected in two different models of sepsis: a model of pneumonia and the cecal ligation and puncture (CLP) polymicrobial model of infection. 30995475 2019
CUI: C0263313
Disease: Pemphigus Foliaceus
Pemphigus Foliaceus 		0.010 GeneticVariation disease BEFREE The rs35336528 (OR = 3·44; P = 0·009) and rs1865097 (OR = 0·57; P = 0·005) SNPs in LENG8 and FCAR genes, respectively, were also associated with PF. 30216441 2019
CUI: C0339901
Disease: Acute respiratory infections
Acute respiratory infections 		0.010 Biomarker group BEFREE Topical application of human-derived Ig isotypes for the control of acute respiratory infection evaluated in a human CD89-expressing mouse model. 31105268 2019
CUI: C0027697
Disease: Nephritis
Nephritis 		0.010 AlteredExpression disease BEFREE Although the molecular features of human IgA1 are different from rodent IgA, human IgA1 knock-in (α1KI)-CD89 transgenic mice, which express both human IgA1 and CD89, show circulating and mesangial deposits of IgA1-soluble CD89 complexes that result in kidney inflammation, hematuria, and proteinuria. 30177023 2018
CUI: C0011608
Disease: Dermatitis Herpetiformis
Dermatitis Herpetiformis 		0.010 Biomarker disease BEFREE A positive correlation was revealed between CD89 immunoexpression and anti-npG IgA in DH. 29417981 2017
CUI: C0037274
Disease: Dermatologic disorders
Dermatologic disorders 		0.010 Biomarker group BEFREE In conclusion, a cream containing IgA or FcαRI peptide mimetics, which block IgA-induced neutrophil activation and migration in the skin may have therapeutic potential for patients with IgA-mediated blistering skin diseases. 28736835 2017
CUI: C0024143
Disease: Lupus Nephritis
Lupus Nephritis 		0.010 Biomarker disease BEFREE Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice. 25907714 2015
CUI: C0022661
Disease: Kidney Failure, Chronic
Kidney Failure, Chronic 		0.010 Biomarker disease BEFREE Understanding how IgA triggers shedding of CD89 from myeloid cell surfaces could help clarify the process of immune complex formation in IgAN, and measurement of this soluble form of CD89 may in the future prove a useful prognostic indicator of end-stage renal disease in this common glomerulonephritis. 21116273 2010
CUI: C2316810
Disease: Chronic kidney disease stage 5
Chronic kidney disease stage 5 		0.010 Biomarker disease BEFREE Understanding how IgA triggers shedding of CD89 from myeloid cell surfaces could help clarify the process of immune complex formation in IgAN, and measurement of this soluble form of CD89 may in the future prove a useful prognostic indicator of end-stage renal disease in this common glomerulonephritis. 21116273 2010
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis 		0.010 Biomarker disease BEFREE As such, we investigated whether IgA-Fc(alpha)RI interaction contributes to tissue damage in UC. 19555692 2009
CUI: C0023473
Disease: Myeloid Leukemia, Chronic
Myeloid Leukemia, Chronic 		0.010 Biomarker disease BEFREE Keeping in view the fact that a single acquired genetic abnormality "Bcr-Abl chimeric gene" accompanied by elevated telomerase activity has been widely recognized to be responsible for the leukemic myelopoiesis observed in chronic myeloid leukemia (CML), the present study was addressed to understand as to how selective and specific knock-down of human telomerase reverse transcriptase (hTERT) gene within mononuclear cells derived from untreated CML subjects could influence the apoptotic, genotypic (such as Bcr-Abl; C-myc; Bcl-2; IL-6; GMCSF; IL-3; and acetylated H(3) and H(4)), and phenotypic (such as CD34 and CD89) characteristics of these cells. 18409031 2008
CUI: C0021368
Disease: Inflammation
Inflammation 		0.010 Biomarker phenotype LHGDN These findings demonstrate that, on monomeric targeting, FcalphaRI functions as an FcRgamma ITAM-dependent apoptotic module that may be fundamental for controlling inflammation and tumor growth. 16990604 2007
CUI: C0024141
Disease: Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic 		0.010 GeneticVariation disease BEFREE These findings and the enrichment of the proinflammatory Gly(248)-FcalphaRI allele in systemic lupus erythematosus populations in two ethnic groups compared with their respective non-systemic lupus erythematosus controls suggest that FcalphaRI (CD89) alpha-chain alleles may affect receptor-mediated signaling and play an important role in the modulation of immune responses in inflammatory diseases. 17339498 2007
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease 		0.010 GeneticVariation disease LHGDN Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. 17008591 2006
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.010 Biomarker disease BEFREE These results suggest that the FCAR promoter SNPs may be related to chronic HCV infection and disease progression in Japanese CHC, which might be explained by altered FcalphaR expression affecting IgA-mediated immune responses and/or IgA catabolism. 17033823 2006
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.010 GeneticVariation disease LHGDN Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin. 17008591 2006
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.010 GeneticVariation disease BEFREE Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin. 17008591 2006
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic 		0.010 GeneticVariation disease BEFREE Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients. 17033823 2006
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic 		0.010 Biomarker disease LHGDN Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients. 17033823 2006
CUI: C1861453
Disease: Pseudohyperkalemia Cardiff
Pseudohyperkalemia Cardiff 		0.010 Biomarker disease BEFREE These results suggest that the FCAR promoter SNPs may be related to chronic HCV infection and disease progression in Japanese CHC, which might be explained by altered FcalphaR expression affecting IgA-mediated immune responses and/or IgA catabolism. 17033823 2006
CUI: C3714514
Disease: Infection
Infection 		0.010 Biomarker group LHGDN Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients. 17033823 2006
CUI: C0001342
Disease: Acute periodontitis
Acute periodontitis 		0.010 GeneticVariation disease BEFREE A novel polymorphism of FcalphaRI (CD89) associated with aggressive periodontitis. 15140034 2004
CUI: C0031106
Disease: Aggressive Periodontitis
Aggressive Periodontitis 		0.010 GeneticVariation disease BEFREE A novel polymorphism of FcalphaRI (CD89) associated with aggressive periodontitis. 15140034 2004
CUI: C0155877
Disease: Allergic asthma
Allergic asthma 		0.010 GeneticVariation disease BEFREE Nevertheless, this is the first report on the distribution of 6 single nucleotide polymorphisms of the FCAR gene in a human population and the first study on FCAR polymorphism in allergic asthma. 15564774 2004
CUI: C0005283
Disease: beta Thalassemia
beta Thalassemia 		0.010 Biomarker disease BEFREE Otherwise, Hb Korea, CDs 89/90 -GT and a novel beta-thalassemia mutation, CD 131 CAG-->TAG, were only identified in Koreans. 12430907 2002